BioCentury
ARTICLE | Company News

Deerfield propels Civetta with $53M series A

How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class

December 5, 2019 1:20 AM UTC
Updated on Dec 7, 2019 at 1:18 AM UTC

Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome.

“There has been over time the emergence of data suggesting the propeller domain as a structure might be more amenable to drug discovery than people had previously thought,” said co-founder William Sellers. “There are close to 500 of these in the human genome, making it one of the most common structural domains.”...

BCIQ Company Profiles

Deerfield Management Co. L.P.